Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

In Vivo CAR-T Development Solutions

Q: Do patients need lymphodepleting chemotherapy for in vivo CAR-T?

One of the main advantages of our in vivo solutions is the potential to reduce or eliminate the need for toxic lymphodepletion, as the cells are programmed within their natural niche.

Online Inquiry

Background Service Platform Workflow Specialty Services Highlights FAQs Contact

Creative Biolabs provides In Vivo CAR-T Development Solutions to overcome challenges associated with conventional cell therapy manufacturing, including high leukapheresis costs, complex ex vivo workflows, and limited product accessibility. By enabling direct T-cell programming through advanced viral vectors and targeted nanoparticle delivery systems, this approach supports scalable, off-the-shelf immunotherapies. We provide integrated contract research services from early platform selection through IND-enabling development and clinical translation, connecting delivery engineering, cellular pharmacology, bioanalysis, toxicology, CMC strategy, and regulatory planning into a single coordinated framework.

Introduction

Traditional adoptive cell therapy is limited by the logistical burden of the living drug paradigms. In vivo engineering via viral or non-viral vectors can effectively reprogram autologous T cells into potent anti-tumor effectors. This method leverages the body's natural environment to maintain T-cell stemness and fitness. In conclusion, in vivo CAR-T engineering represents a transformative off-the-shelf solution that expands the reach of immunotherapy to solid tumors and autoimmune diseases globally.

Fig.1 In vivo CAR Cell Therapy: Mechanisms of Viral versus Non‑Viral Vectors. (OA Literature) Fig.1 Mechanisms of in vivo CAR cell therapy using viral and non viral vectors.¹

Our Service

Leveraging extensive expertise in cell engineering, Creative Biolabs has established a CellRapeutics™ in vivo cell engineering development platform to support the development of next-generation immune cell therapies. Our platform integrates viral and non-viral delivery technologies, including targeted lentiviral vectors, engineered particles, virus-like particles, lipid nanoparticles, mRNA/circular RNA systems, polymeric nanoparticles, and extracellular vesicles, for precise in vivo programming of immune cells.

We provide delivery platform evaluation and optimization by assessing particle characteristics, cargo quality, targeting specificity, cellular uptake, transgene expression, functional activity, and safety profiles. Through comparative screening and engineering optimization, we identify delivery systems with the optimal balance of T-cell selectivity, expression control, therapeutic potency, manufacturability, and clinical translation potential.

Discover How We Can Help - Request a Consultation.

Advanced In Vivo CAR Platform

Lentiviral Vector Platform. (AI Generation)

Lentiviral Vector Platform

Creative Biolabs provides a lentiviral vector platform that enables permanent genomic integration for the durable treatment of hematological malignancies. Advanced pseudotyping ensures precise T-cell targeting, while Tier-1 impurity control minimizes risks from random insertion and off-target infection.

Learn More →

tLNP-mRNA Platform. (AI Generation)

tLNP-mRNA Platform

Our tLNP-mRNA platform provides a non-integrative approach focused on safety and scalability, achieving up to 85% transduction efficiency with low risk of cytokine release syndrome. Its transient expression makes it well-suited for autoimmune diseases where precise dose control is essential.

Learn More →

Targeted Integration Platform. (AI Generation)

Targeted Integration Platform (EDV/AAV)

This Targeted Integration Platform leverages Enveloped Delivery Vehicles (EDV) to deliver Ribonucleoproteins for precise TRAC locus cleavage and Adeno-Associated Virus vectors (AAV) for CAR template delivery. Using the endogenous TRAC promoter ensures physiological receptor expression, reducing cell exhaustion and enhancing long-term anti-tumor efficacy.

Learn More →

Technical Comparison Table

Choosing the right vehicle determines not just the efficacy of the drug, but its regulatory fate and commercial viability.

Feature	Lentiviral Platform	tLNP-mRNA Platform	Targeted Integration
Integration	Random	None (Transient)	Site-Specific
Persistence	Permanent	Short-term	Permanent
Risk Profile	Insertion Mutagenesis	Minimal (Safe)	Optimized (Controlled)
Manufacturing	Complex	Streamlined	High Engineering Complexity
Primary Indication	Leukemia/Lymphoma	Autoimmune Diseases	Solid Tumors

Our Workflow

Workflow of In Vivo CAR-T Engineering. (Creative Biolabs Original)

This deliverable includes an analytical report with vector characterization, titration data, and in vitro/in vivo efficacy results; high-resolution raw sequencing and flow cytometry datasets for T-cell phenotyping and CAR integration site analysis; and a stabilized pilot-scale batch of the optimized engineered viral or non-viral delivery vehicle for further development.

Representative CAR Design Types

Established CAR formats featuring optimized antigen-binding domains and intracellular signaling modules across multiple generations.

CAR Design	Architecture	Key Features
First-generation CARs	scFv-Hinge-TM-CD3Z	Provides antigen-specific activation through CD3Z signaling only
Second-generation CARs	scFv-TM-Costimulatory domain-CD3Z	Adds one costimulatory domain to improve proliferation, persistence, and cytotoxicity
Third-generation CARs	scFv-TM-CD28-4-1BB-CD3Z	Incorporates dual costimulatory domains for enhanced activation and durability
Fourth-generation (TRUCK)	CAR + cytokine expression cassette	Enables cytokine secretion to remodel the tumor microenvironment
Fifth-generation CAR	CAR + intracellular cytokine signaling motifs	Integrates antigen recognition with cytokine pathways to enhance persistence

Advanced CAR strategies enabling simultaneous recognition of multiple antigens to improve coverage and prevent tumor escape.

CAR Design	Architecture	Key Features
Dual CAR	Two independent CARs co-expressed in one cell	Targets multiple antigens to reduce antigen escape
Tandem CAR (TanCAR)	Tandem scFv1-linker-scFv2-TM-Signaling domain	Enables dual-antigen recognition within a single CAR molecule
Bispecific CAR	Bispecific antigen-binding domain-Signaling domain	Improves antigen coverage and therapeutic robustness
Tri-specific CAR	Three antigen-binding modules-Signaling domain	Provides broader recognition against heterogeneous tumors
Dual-target CAR-NK	Multi-antigen CAR optimized for NK cells	Combines multi-target recognition with NK cell activity

Innovative CAR systems integrating controllable, logic-gated, and switchable functions for enhanced precision and safety.

CAR Design	Architecture	Key Features
Universal CAR	Universal receptor + soluble targeting adaptor	Separates antigen recognition from CAR activation for flexible targeting
Switchable CAR	CAR receptor + switch molecule	Enables controllable CAR activation and target switching
Logic-gated CAR	Dual-input recognition circuit	Requires multiple signals for selective activation
SynNotch CAR	Synthetic receptor-mediated CAR expression	Uses one antigen to trigger expression of another CAR
NOT-gate CAR	Activating CAR + inhibitory receptor	Prevents recognition of healthy tissues expressing protective antigens
Suicide CAR	CAR + inducible elimination switch	Provides an emergency safety mechanism for CAR-cell removal

Novel CAR formats using diverse recognition elements beyond conventional scFv-based antigen targeting approaches.

CAR Design	Architecture	Key Features
NKG2D CAR	Full-length NKG2D receptor-CD3ζ	Targets multiple stress ligands, including MHC class I polypeptide-related sequences A/B (MICA/B) and UL16-binding proteins (ULBPs)
Ligand-based CAR	Natural ligand domain-Signaling domain	Uses endogenous ligand-receptor interactions for recognition
Fab-based CAR	Fab fragment-TM-Signaling domain	Alternative antigen-binding format to optimize CAR performance
TCR-like CAR	Peptide-HLA recognition domain-Signaling domain	Enables recognition of intracellular tumor antigens
Peptide-centric CAR	Peptide-MHC recognition module-Signaling domain	Expands CAR targeting beyond surface antigens
CAR-NK	CAR optimized for NK cells	Leverages NK-mediated cytotoxicity and potential off-the-shelf applications
CAR-M	CAR + macrophage activation modules	Enhances phagocytosis and tumor microenvironment modulation

T-Cell Targeting Strategy

Precision delivery requires absolute cell-type discrimination. We ensure your vector targets relevant T-cell subsets while sparing off-target lineages, validated by an assay cascade that evaluates physical uptake through to CAR expression, activation, and long-term memory phenotypes.

Targeting Vectors: Validated strategies directed against CD3, CD4, CD5, CD7, CD8, and custom cell-surface receptors.
Multilayer Specificity: Synergy combining surface ligand optimization with T-cell-selective promoters, microRNA detargeting, fine-tuned binding affinity, and post-transcriptional control mechanisms.
Physiologically Relevant Models: Selectivity validation across whole blood, PBMCs, isolated immune subsets, patient-derived samples, and complex disease co-cultures.

CAR Payload Design & Functional Characterization

We optimize CAR constructs to achieve robust, controllable expression and potent functional responses tailored for complex in vivo environments.

Architecture Optimization: Evaluate construct elements (scFv, hinge, TM, costimulatory domains, promoters, UTRs, RNA formats) tailored for heterogeneous in vivo T-cell expression.
Functional Testing: Assess CAR expression density, cytotoxicity, serial killing, cytokine release, proliferation, tonic signaling, exhaustion, and on-target/off-tumor activity.
Expression Strategy: Measure onset and kinetics for transient RNA systems, or analyze vector copy number, stability, and integration safety for integrating platforms.

Specialty Services

Engineered In Vivo Platforms for Diverse Immune Cell Types

Creative Biolabs develops engineered in vivo immune cell platforms beyond conventional CAR-T applications, enabling targeted programming of diverse immune populations including T cells, NK cells, macrophages, and other therapeutic effectors. Through optimized delivery systems and genetic engineering strategies, these platforms support the development of next-generation immunotherapies.

In Vivo CAR-T Cell Engineering Services

Creative Biolabs provides in vivo CAR-T engineering services that enable direct genetic modification of T cells within the body, supporting efficient cell programming, scalable manufacturing, and improved therapeutic potential.

Learn More →

In Vivo B Cell Engineering Service

Creative Biolabs offers in vivo B cell engineering to program antibody-producing cells directly in the body, enabling durable therapeutic protein expression and innovative immunotherapy strategies.

Learn More →

In Vivo CAR-NK Cell Engineering Service

We develop in vivo CAR-NK engineering platforms to generate functional CAR-NK cells within the body, enhancing innate immune targeting and expanding next-generation cell therapy options.

Learn More →

In Vivo CAR-M Cell Engineering Service

Creative Biolabs provides in vivo CAR-macrophage engineering solutions to program macrophages for tumor recognition, phagocytosis, and immune modulation within complex tumor microenvironments.

Learn More →

In Vivo Peripheral Blood Mononuclear Cell Engineering

We enable in vivo engineering of PBMC populations, facilitating direct modification of immune cells to support flexible and scalable development of advanced cell-based immunotherapies.

Learn More →

In Vivo CAR Safety Assessment & Bioanalysis

We map the complex dose-response relationship of in vivo CAR-T therapies by connecting vector dose to T-cell kinetics and clinical response. Our bioanalytical assays measure vector PK, tissue distribution, vector copy number, T-cell expansion/phenotypes, and immunogenicity. This data feeds into mechanistic PK/PD and cellular-kinetic models to guide rational, model-informed dose selection.

End-to-End Flow Cytometry Solutions for In Vivo CAR-T/NK/M Innovation

Accelerate your in vivo CAR-T and CAR-NK innovations with our end-to-end flow cytometry solutions. We deliver seamless workflows from high-throughput cell profiling and target validation to deep immune monitoring and functional characterization. By combining advanced multivariable panels with precise analytical capabilities, our platform ensures robust, reproducible data at every step—empower your translational research to bring next-generation targeted cell therapies from discovery to clinical application faster.

Learn More →

One-stop In Vivo CAR Safety Assessment Services

Comprehensive safety evaluation solutions for in vivo CAR therapies, covering biodistribution, genomic integration, immunogenicity, toxicity assessment, and long-term persistence analysis to identify potential risks, support regulatory requirements, and accelerate clinical translation of next-generation CAR platforms.

Learn More →

In Vivo CAR Bioanalysis & Testing Services

Integrated bioanalytical characterization of in vivo CAR therapies using advanced molecular and cellular assays, including vector quantification, CAR expression monitoring, pharmacokinetic and pharmacodynamic analysis, immune profiling, and functional evaluation to support therapeutic development and translational studies.

Learn More →

CAR-T Preclinical Translation & Development Strategy

Translational PharmacologySafety EngineeringPreclinical DevelopmentCMC Development

In vivo CAR-T therapies exhibit complex, nonlinear dose-response relationships where vector exposure directly dictates cellular expansion, therapeutic efficacy, and toxicity. We deliver integrated bioanalytical strategies to model these dynamic interactions and guide informed dose selection.

Pharmacokinetics & Biodistribution: Quantitative profiling of vector kinetics, tissue distribution, clearance, persistence, and shedding.
Cellular Kinetics & Dynamics: Tracking vector copy number (VCN), CAR expression (DNA/RNA/protein), CD4/CD8 phenotyping, and long-term T-cell expansion and contraction.
Biomarker & Efficacy Readouts: Monitoring target-cell depletion and recovery alongside cytokine and inflammatory biomarker panels.
Immunogenicity Assessment: Rigorous screening for anti-vector and anti-transgene immune responses.
Mechanistic PK/PD Modeling: Translating raw bioanalytical data into cellular-kinetic models to directly link vector dose with functional, in vivo CAR-T activity.

FAQs

Q: How do you ensure the vector only targets T cells in vivo?

A: We utilize surface-engineered envelopes or ligand-functionalized nanoparticles that specifically recognize T-cell markers like CD3. This ensures that the genetic payload is internalised only by the intended immune cells.

Q: Can we use mRNA instead of viral DNA for the CAR construct?

A: Our nanoparticle platform is optimized for mRNA delivery, which allows for transient CAR expression. This is particularly useful for managing safety and toxicity in early-phase research.

Q: What is the risk of off-target integration with viral vectors?

A: We employ integration-deficient or T-cell-specific viral systems and perform integration site analysis to ensure safety and minimize the risk of insertional mutagenesis.

Q: Do patients need lymphodepleting chemotherapy for in vivo CAR-T?

A: One of the main advantages of our in vivo solutions is the potential to reduce or eliminate the need for toxic lymphodepletion, as the cells are programmed within their natural niche.

Partner with Us

Creative Biolabs provides a revolutionary In vivo CAR-T Engineering platform that replaces complex ex vivo manufacturing with precise in situ programming. Supporting everything from custom vector design to thorough in vivo validation, we offer a streamlined workflow for developing affordable, scalable, and highly potent immunotherapies. To learn more or discuss your project needs, please contact us. Our professional team is ready to assist with your customized requirements.

Reference

Yang, Yi-Min et al. "In vivo CAR-cell therapy: current challenges and emerging therapeutic advances." Molecular biomedicine vol. 7,1 54. 20 Apr. 2026. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s43556-026-00447-y

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.